Frequency of Thyroid Dysfunctions during Interferon Alpha Treatment of Single and Combination Therapy in Hepatitis C Virus-Infected Patients: A Systematic Review Based Analysis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Nair Kesavachandran, Chandrasekharan ^a,c   Haamann, Frank ^b   Nienhaus, Albert ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Occupational Health Research ^*  (Germany)

^c CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; CONSENSUS INTERFERON; IODINE; LEVOVIRIN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2 INTERFERON; RIBAVIRIN;

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; ETHNICITY; GENETIC PREDISPOSITION; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HUMAN; HYPOTHYROIDISM; INCIDENCE; IODINE DEFICIENCY; MASS SCREENING; MONOTHERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW; THYROID DISEASE; THYROID FUNCTION TEST; THYROIDITIS; THYROTOXICOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INCIDENCE; INTERFERON-ALPHA; RISK ASSESSMENT; THYROID DISEASES; THYROID FUNCTION TESTS;

EID: 84873269405     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055364     Document Type: Article

References (92)

1. World Health Organisation (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organised in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6(1): 35-47.
2. EASL (European Association on the studies on the Liver) (1999) EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 31 (1): 3-8.
3. Tomer Y, Blackard JT, Akeno N, (2007) Interferon alpha treatment and thyroid dysfunction. Endocrinol Metabol Clin North Am 36 (4): 1051-66.
4. Dusheiko G, (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26 (3. 1): 112S-121S.
5. Russo MW, Fried MW, (2003) Side effects of therapy for chronic hepatitis C. Gastroenterology. 124: 1711-1719.
6. Fattovich G, Giustina G, Favarato S, Ruol A, (1996) A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with α interferon. J Hepatol 24: 38-47.
7. Trans HA, Reeves GEM, Gibson R, Attia JR, (2009) Development of thyroid diseases in the treatment of chronic hepatitis C with α interferon may be a good prognosticator in achieving a sustained virological response: A metaanalysis. J Gastroenterol Hepatol 24: 1163-1168.
8. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, et al. (2001) Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 32. (9): 904-9.
9. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, et al. (1996) Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-α. Am J Med 101: 482-487.
10. Mazziotti G, Sorvillo F, Stornaiuolo G, Rotondi M, Morisco F, et al. (2002) Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest 25: 624-630.
11. Villanueva RB, Brau N, (2002) Graves' ophthalmopathy associated with interferon-αtreatment for hepatitis C. Thyroid. 12: 737-738.
12. Kryczka W, Brojer E, Kowalska A, Zarebska-Michaluk D, (2001) Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Med Sci Monit. 7(Suppl 1): 221-5.
13. Manns MP, Wedemeyer H, Cornberg M, (2006) Treating viral hepatitis C: efficacy, side effects and complications. Gut 55: 1350-1359.
14. Wang SH, Bretz JD, Phelps E, Mezosi E, Arscott PL, et al. (2002) A unique combination of inflammatory cytokines enhances apoptosis of thyroid follicular cells and transforms nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. J Immunol 168: 2470-2474.
15. Hultgren C, Milich DR, Weiland O, Sallberg M, (1998) The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 79: 2381-2391.
16. Carella C, MazziottiG, Amato G, Braverman LE, Roti E, (2004) Clinical review 169: Interferon alpha related thyroid disease: pathophysiological, epidemiological and clinical aspects. J Clin Endocrinol Metab 89 (8): 3656-61.
17. Tran HA, Attia JR, Jones TL, Batey RG, (2007) Pegylated interferon α2β in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon α2β in hepatitis C population: Meta-analysis. J Gastroenterol Hepatol 22: 472-476.
18. Prummel MF, Laurberg P, (2003) Interferon- α and autoimmune thyroid disease. Thyroid 13: 547-551.
19. Chan WB, Chow CC, Cockram CS, (2003) Interferon alpha treatment and endocrine disease. J Royal Soc Med 96: 481-485.
20. Marcellin P, Pouteau M, (1995) Benhamon (1995) Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 22: 364-369.
21. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7): e1000097 doi:10.1371/journal.pmed.1000097.
22. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, et al. (2001) Long-term outcome of interferon α induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 86: 1925-1929.
23. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alpha 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
24. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N, (1994) The risk factor for development of thyroid disease during interferon-α therapy for chronic hepatitis C. Am J Gastroenterol. 89: 399-403.
25. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, et al. (1992) Development of thyroid disease during therapy of chronic viral hepatitis with interferon α. Gastroenterol 102: 2155-2160.
26. Kim B K, Choi Y S, Park Y H, Lee S U, (2011) Interferon-alpha-induced destructive thyroiditis followed by Graves' Disease in a patient with chronic hepatitis C: A case report. J Korean Med Sci 26: 1638-1641.
27. Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, et al. (2002) The addition of ribavirin to interferon-α therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 146: 743-749.
28. Monzani F, CaraccioN,Dardano A, Ferrannini E, (2004) Thyroid autoimmunity and dysfunction associated with type 1 interferon therapy. Clin Exp Med 3(4): 199-210.
29. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, et al. (1997) Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon α therapy. Hepatol 26: 206-210.
30. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, et al. (1998) Increased risk of autoimmune thyroid disease in hepatitis C vs. hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 158: 1445-1448.
31. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, et al. (1996) Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 25: 283-291.
32. Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, et al. (2000) Virologic factors related to interferon alpha induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol. 142: 431-437.
33. Floreani A, Chiaramonte M, Greggio NA, Fabris P, De Lazzari F, et al. (1998) Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients. Ital J Gastroenterol Hepatol 30: 71-76.
34. Baudin E, Marcellin P, Pouteau M, Colas-Linhart N, Le Floch JP, et al. (1993) Reversibility of thyroid dysfunction induced by recombinant α interferon in chronic hepatitis C. Clin Endocrinol (Oxf). 39: 657-661.
35. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, et al. (1993) High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatol 18: 253-257.
36. Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M, (1999) HLA antigens in patients with interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol. 30: 794-800.
37. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, et al. (1995) Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon α-2a. Eur J Endocrinol 132: 587-593.
38. Loviselli A, Oppo A, Velluzzi F, Atzeni F, Mastinu GL, et al. (1999) Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in northwestern Sardinia. J Endocrinol Invest 22: 660-665.
39. Rose NR, Rasooly L, Saboori AM, Burek L, (1999) Linking iodine with autoimmune thyroiditis. Environ Hlth Perspect 107: 749-752.
40. Minelli R, Braverman LE, Valli MA, Schianchi C, Pedrazzoni M, et al. (1999) Recombinant interferon α (rIFN-α) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patients with HCV chronic active hepatitis. Clin Endocrinol (Oxf) 50: 95-100.
41. Bini EJ, Mehandru S, (2004) Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 164(21): 2371-2376.
42. Imagawa A, Itoh N, Hanafusa T, Oda Y, Waguri M, et al. (1995) Autoimmune endocrine disease induced by recombinant interferon α therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 80: 922-926.
43. Ramos-Casals M, Trejo O, García-Carrasco M, Font F, (2003) Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatol 42: 818-28.
44. Gupta VK, Kotwar NK, Jha A, Menon AS, Shukla R, (2011) A case of Interferon induced Hypothyroidism. MJAFI 67: 1.
45. Nagayama Y, Kazuhiroo HTA, Suruta MT, Akeshita A, Kimura H, et al. (1994) Exacerbation of thyroid autoimmunity by interferon α treatment in patients with chronic viral hepatitis: Our studies and review of the literature. Endocr Jl 41 (5): 562-572.
46. Mandac JC, Chaudhry S, Sherman KE, Tomer Y, (2006) The Clinical and Physiological Spectrum of Interferon- Alpha Induced Thyroiditis: Toward a New Classification. Hepatol 43: 661-672.
47. Testa P, Castaldi V, Fant GF, Fiore V, Grieco A, et al. (2006) Prevalence of HCV antibodies in autoimmune thyroid disease. Eur Rev Med Pharmacol Sci 10: 183-186.
48. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, et al. (2004) Thyroid disorders in chronic hepatitis C. Am J Med. 117(1): 10-3.
49. Dalgard O, Bjoro K, Hellum K, Myrvang B, Bjoro T, et al. (2002) Thyroid dysfunction during treatment of chronic hepatitis C with interferon α: no association with either interferon dosage or efficacy of therapy. J Intern Med 251: 400-406.
50. Nadeem A, Aslami M, Khan DA, Hussain T, Khan SA, (2009) Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C. J Coll Physic Surg Pak 19. (2): 86-90.
51. Yan Z, Fan K, Fan Y, Wang X, Mao Q, et al. (2012) Thyroid dysfunction in Chinese patients with chronic hepatitis C treated with interferon alpha: Incidence, long term outcomes and predictive factors. Hepat Mon 12 (9): e6390 DOI:10.5812/hepatmon.6390.
52. European Association for the Study of the Liver, (2011) EASL Clinical Practice Guidelines: Management of hepatitis C. J Hepatol. 55: 245-264.
53. Ghany MG, Strader DB, Thomas DL, Seeff B, (2009) American Association for the study of liver diseases practice guidelines-Diagnosis, management and treatment of Hepatitis C: An update. Hepatology 49(4): 1335-1374.
54. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
55. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
56. Hadziyannis SJ, SetteHJr, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
57. Barut S, Gunal O, Erkorkmaz U, Yildiz F, (2012) Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010. Braz J Infect Dis 16(5): 448-51.
58. Kim BK, Choi YS, Park YH, Lee SU, (2011) Interferon-alpha-induced destructive thyroiditis followed by Graves' disease in a patient with chronic hepatitis C: a case report. J Korean Med Sci 26(12): 1638-41.
59. Vasiliadis T, Anagnostis P, Nalmpantidis G, Soufleris K, Patsiaoura K, et al. (2011) Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C. Ann Acad Med Singapore. 40(9): 394-400.
60. Andrade LJ, Atta AM, Atta ML, Mangabeira CN, Paraná R, (2011) Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy. Braz J Infect Dis 15(4): 377-81.
61. Dabrowska MM, Panasiuk A, Flisiak R, (2010) Thyroid dysfunction in antiviral therapy of chronic hepatitis C. Hepatogastroenterol. 57(101): 826-31.
62. Costelloe SJ, Wassef N, Schulz J, Vaghijiani T, Morris C, et al. (2010) Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy. Clin Endocrinol (Oxf) 73(2): 249-56.
63. Tran HA, Reeves GE, (2009) The Spectrum of Autoimmune Thyroid Disease in the Short to Medium Term Following Interferon-alpha Therapy for Chronic Hepatitis C. Int J Endocrinol. 2009: 241786 Doi:10.1155/2009/241786.
64. Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G, (2009) Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? J Gastroenterol Hepatol 24(6): 1024-9.
65. Jamil KM, Leedman PJ, Kontorinis N, Tarquinio L, Nazareth S, et al. (2009) Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol. 24(6): 1017-23.
66. Masood N, Ghori R, Memon A, Memon S, Memon KI, et al. (2008) Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection. J Coll Physicians Surg Pak 18(6): 347-51.
67. Tran HA, Jones TL, Batey RG, (2005) The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin.BMC Endocr Disord 12. 5: 8.
68. Parana R, Cruz M, Santos-Jesus R, Ferreira K, Codes L, et al. (2000) Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin. Braz J Infect4: 284-290.
69. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, et al. (2005) Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatol. 41: 1013-1018.
70. Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, et al. (2006) Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol 21: 319-26.
71. Gehring S, Kullmer U, Koeppelmann S, Gerner P, Wintermeyer P, et al. (2006) Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha. World J Gastroenterol 28 12(36): 5787-92.
72. Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Słuzewski W, (2007) Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiol drug saf. 16: 1095-1103.
73. Plockinger U, Kruger D, Bergk A, Weich V, Wiedenmann B, et al. (2007) Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. Amer J Gastroenterol 102: 2724-2731.
74. Tran HA, Reeves GE, Jones TL, (2009) The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. QJM 102: 117-122.
75. Tran HA, Jones TL, Ianna EA, Reeves GE, (2011) The natural history of interferon-a induced thyroiditis in chronic hepatitis c patients: a long term study. Thyroid Res 8 4(1): 2 Doi:10.1186/1756-6614-4-2.
76. Moncoucy X, Leymavie F, Delemer B, Levy S, Bernard-Chabert B, et al. (2005) Risk factors and long term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol. 29: 339-345.
77. Gowans EJ. Distribution of markers of hepatitis C virus infection throughout the body. Semin Liver Dis 20: 85-102.
78. Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, et al. (2007) Host and viral factors in the immuno pathogenesis of primary hepatitis C virus infection. Immuno Cell Biol 85: 24-32.
79. Huang JF, Chuang WL, Dai CY, Chen SC, Lin ZY, et al. (2006) The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. J Viral Hepat 13(6): 396-401.
80. Murakami M, Kakizaki S, Takayama H, Takagi H, Mori M, (1999) Autoimmune thyroid disease induced by interferon therapy. Nippon Rinsho 57: 1779-83.
81. Carella C, Amato G, Biondi B, Rotondi M, Morisco F, et al. (1995) Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 44: 110-14.
82. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, García-Monzón C, Arranz A, et al. (1996) Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 44: 635-42.
83. Wong V, Fu AX, George J, Cheung NW, (2002) Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 56(6): 793-8.
84. Morisco F, Mazziotti G, Rotondi M, Tuccillo C, Iasevoli P, et al. (2001) Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. Dig Liver Dis. 33(3): 247-53.
85. Rocco A, Gargano S, Provenzano A, Nardone M, De Sanctis GM, et al. (2001) Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. Neuro Endocrinol Lett 22(1): 39-44.
86. Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C, (2009) Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol. 15(3): 328-33.
87. Doi F, Kakizaki S, Takagi H, Murakami M, Sohara N, et al. (2005) Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. 25(2): 242-6.
88. Berris B, Feinman SV, (1991) Thyroid dysfunction and liver injury following interferon treatment of chronic viral hepatitis. Dig Dis Sci 36: 1657-1660.
89. Pateron D, Hartmann DJ, Duclos-Vallee JC, Jouanolle H, Beaugrand M, (1993) Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 17(3): 417-419.
90. Kodama T, Katabami S, Kamijo K, Katanuma A, Yamashita K, et al. (1994) Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon. J Gastroenterol 29(3): 289-92.
91. Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J, (2009) Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. J Viral Hepat. 16(3): 168-77.
92. Krupinska J, Wawrzynowicz-Syczewska M, Urbanowicz W, Poblock J, Syrenicz A, (2011) The influence of interferon alpha on the induction of autoimmune thyroiditis patients treated for chronic viral hepatitis type C. Endokrynol Pol. 62(6): 517-22.